BioXcel Therapeutics (BTAI) Tops Q4 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BioXcel Therapeutics (BTAI) PT Lowered to $7 at BofA Securities
March 13, 2024 6:13 AM EDTBofA Securities analyst Geoff Meacham lowered the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $7.00 (from $8.00) while maintaining a Buy rating.
The analyst comments "BioXcel announced a 4Q23 update as the company continues to finalize the clinical programs (see report) designed... More
